ELAN Elanco (ELAN) Q2 FY26 earnings call
Elanco delivered robust Q2 FY26 results, driven by strong innovation in U.S. Pet Health and Farm Animal segments, leading to an 8% organic constant currency revenue growth. The company raised its full-year outlook for revenue, adjusted EBITDA, and adjusted EPS, while accelerating net leverage reduction. Management emphasized the durability of the animal health market and the effectiveness of its IPP strategy, despite shifts in pet owner purchasing behaviors.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ELAN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Reorder rate Zenrelia - US | 80%+We're now in about half of the clinics in the US and the reorder rate is over 80%.Source: earnings call transcript | 80%+That's greater than 60% of the total clinic base with a reorder rate maintained at over 80%.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.